Therapeutic Asset Ratings

3,848 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Jcar017 (Lisocabtagene Maraleucel) High-Grade B-Cell Lymphoma, Nos	Fred Hutchinson Cancer Center	P2	BB (65)
Jcar017 (Lisocabtagene Maraleucel) Recurrent Primary Mediastinal Large B-Cell Lymphoma	Fred Hutchinson Cancer Center	P2	BB (65)
Av-Gbm-1 Newly Diagnosed Glioblastoma	Aivita Biomedical, Inc.	P3	BB (64)
Jcar017 (Lisocabtagene Maraleucel) Recurrent Diffuse Large B-Cell Lymphoma	Lyell Immunopharma, Inc.	P3	BB (64)
Lifileucel Clinical Stage IV Cutaneous Melanoma AJCC v8	Iovance Biotherapeutics, Inc.	P3	BB (64)
Rondecabtagene Autoleucel Relapsed Non-Hodgkin Lymphoma	Lyell Immunopharma, Inc.	P3	BB (64)
Tabelecleucel Lymphoproliferative Disorders	Pierre Fabre Medicament	P3	BB (64)
Tisagenlecleucel B-cell Acute Lymphoblastic Leukemia	Assistance Publique - Hôpitaux de Paris	P3	BB (64)
Tisagenlecleucel Diffuse Large B Cell Lymphoma	University of Utah	P3	BB (64)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Myeloproliferative Neoplasm	Fred Hutchinson Cancer Center	P2	BB (64)
Brexucabtagene Autoleucel Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia	Kite, A Gilead Company	P2	BB (64)
cd19-ucart B-cell Acute Lymphoblastic Leukemia	Beijing GoBroad Hospital	P2	BB (64)
Tisagenlecleucel Primary Mediastinal Large B Cell Lymphoma	SWOG Cancer Research Network	P2	BB (64)
Anti-Cea Car-T Cells Malignant Tumor of Pancreas Metastatic to Liver	Sorrento Therapeutics, Inc.	P2/3	BB (64)
Prizloncabtagene Autoleucel Non-Hodgkin's B-cell Lymphoma	Janssen Research & Development, LLC	P1/2	BB (64)
Anti-Bcma Car-T Cells Multiple Myeloma	Thomas Martin, MD	P3	B (63)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription Sickle Cell Disease	Vertex Pharmaceuticals Incorporated	P3	B (63)
Tisagenlecleucel Acute Lymphoblastic Leukemia	Stanford University	P3	B (63)
Allogeneic Adipose-Derived Mesenchymal Stem Cells Diabetic Foot Ulcer	Medical University of Warsaw	P2	B (63)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Acute Myelogenous Leukemia	David Wald	P2	B (63)
cd19-ucart Acute Lymphoblastic Leukemia	Zhujiang Hospital	P2	B (63)
Chimeric Antigen Receptor Modified T Cells Infusion Acute Lymphoblastic Leukemia	King Faisal Specialist Hospital & Research Center	P2	B (63)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs AML	Fred Hutchinson Cancer Center	P2/3	B (63)
cd22 car-transduced t cells Lymphoma, B-Cell	Kecellitics Biotech Company Ltd	P1/2	B (63)
Dc-Cik Colorectal Cancer	ShiCang Yu	P4	B (62)

Showing 51 to 75 of 3,848 assets

PreviousPage 3 of 154Next